Edesa Biotech, Inc.
CIK: 0001540159
Company Information
Financial Overview
FY2024
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-Q Quarterly financial report | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 424B5 Prospectus supplement | December 12, 2025 | View on SEC |
| 8-K Current report of material events | December 12, 2025 | View on SEC |
| 8-K Current report of material events | December 12, 2025 | View on SEC |
| 10-K Annual financial report | December 12, 2025 | View on SEC |
| 4 Insider stock transaction report | December 2, 2025 | View on SEC |
Annual Reports
10-K December 12, 2025
- Secured capital through various channels including preferred stock, warrants, and ATM offerings.
- Utilized a revolving credit facility and participated in the Canada Emergency Business Account Program (CEBA).
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.